David W. Carley

Chief Tech/Sci/R&D Officer at Pier Pharmaceuticals, Inc.

Health Technology

Consumer Services

Finance

Profile

David W.
Carley is currently the Director & Chief Scientific Officer at Pier Pharmaceuticals, Inc. and a Professor at the University of Illinois.
He was formerly a Director at RespireRx Pharmaceuticals, Inc. Carley received a doctorate degree from Harvard University in 1985, a doctorate degree from Massachusetts Institute of Technology, and a graduate degree from Massachusetts Institute of Technology in 1982.

David W. Carley active positions

Companies	Position	Start
Pier Pharmaceuticals, Inc. Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO.	Chief Tech/Sci/R&D Officer	2011-06-28
University of Illinois	Corporate Officer/Principal	2011-06-28

All active positions of David W. Carley

Former positions of David W. Carley

Companies	Position	End
RESPIRERX PHARMACEUTICALS INC.	Director/Board Member	-

See the detail of David W. Carley's experience

Training of David W. Carley

Massachusetts Institute of Technology	Graduate Degree
Harvard University	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David W. Carley's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
RESPIRERX PHARMACEUTICALS INC.	Health Technology

Private companies	1
Pier Pharmaceuticals, Inc. Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO.	Health Technology